|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||1.52 / 11.11|
Here's a technical look at how to trade five stocks trading for less than $10 a share.
Evoke Pharma (EVOK) shares continue to fall today after the company's diabetic gastroparesis trials missed topline results on Monday.
Evoke Pharma’s (EVOK) diabetic gastroparesis drug missed its primary endpoint in phase 3 topline results.
205 subjects complete the study
Further Safety of EVK-001 Demonstrated with TQT Results
Provides Outlook for Completing Phase 3 Clinical Trial and Upcoming NDA Submission
NDA Preparation Initiates as EVK-001 Nears Phase 3 Study Completion
186 of 200 Subjects Enrolled in Phase 3 Clinical Trial of EVK-001
Clinical Data Support Cardiac Safety of EVK-001
Enhanced Financial Strength and Further Progressed Trial Enrollment
Provides Additional Support for Completion of Phase 3 Trial and Submission of New Drug Application (NDA)
150 Patients Enrolled in Phase 3 Clinical Trial
States Patients With Diabetic Gastroparesis May Have Unpredictable Gastric Emptying and Altered Absorption of Orally-Administered Hypoglycemic Drugs